HC Wainwright & Co. reiterates Buy rating on Nektar Therapeutics, $185 price target

HC Wainwright & Co. maintained a Buy rating on Nektar Therapeutics with a $185 price target, suggesting a 293.7% upside from the Oct 1 close of $46.99. The firm cited strong Phase 2b data for rezpeg and an undervalued stock as reasons for the recommendation.

Original reporting
Published Oct 2, 2026, 11:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 11:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. reiterates Buy rating on Nektar Therapeutics, $185 price target — source image
Decision brief

The 30-second read

$NKTRBullishMed
01

Why it matters

The upgrade could trigger buying pressure, especially among traders focused on biotech catalysts.

02

Market read

The new trial data and aggressive price target provide a fresh catalyst for NKTR, potentially moving the stock higher in the short term.

03

What to watch

Potential competition and regulatory timelines could dampen upside.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Analyst note from HC Wainwright highlighting new Phase 2b data for rezpeg and issuing a $185 price target.

Company-level read

Ticker impact

$NKTRBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on Nektar Therapeutics and set a new $185 price target based on fresh Phase 2b REZOLVE-AA data.

Expected impact

likely upward pressure as investors price in the upgraded target and trial data.

Evidence & confidence

The combination of new efficacy data and a 293% upside target provides a clear catalyst for buying interest.

Market effects

Biotech sector may see renewed interest in oncology trials after positive Phase 2b results.

U.S. biotech investors could allocate more capital to NKTR and peers.

Limited to investors tracking clinical-stage biotech pipelines.

Counterpoint

The Phase 2b data may not translate to Phase 3 success, making the $185 target overly optimistic.

Key entities

  • Nektar Therapeutics

    Biopharma developing rezpeg for oncology.

  • HC Wainwright & Co.

    Equity research firm issuing the Buy rating.

Related articles

$NKTRMed

Nektar (NKTR) Q3 2026 Earnings Call Transcript

Nektar (NKTR) discussed its Q3 2026 earnings, highlighting the potential of REZPEG, a novel treatment for atopic dermatitis and alopecia areata. The company reported positive phase II data and plans for phase III trials, aiming for a broad label. REZPEG targets multiple inflammatory pathways, addressing unmet needs in the $30B+ U.S. eczema market. Nektar expects top-line data in 2028 and a BLA filing by late 2029.

$NKTRLow

In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics reported $952.9 million in cash and…

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD. In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics (the “Company”) reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consistent with its prio

$NKTRMedAI 8/10

What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call

Nektar Therapeutics (NKTR) reported Q3 earnings, highlighting clinical trial progress and updated financial guidance. The company expects to complete enrollment in three studies by January 2028 and report one-year data from the REZOLVE-AD study in Q1 2027. Nektar plans additional studies for alopecia, vitiligo, and type 1 diabetes. The company raised its cash outlook to over $840M for 2026, with Q3 net loss of $56M. Research and development expenses are projected to increase in Q4.